Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diclofenac + paracetamol + serratiopeptidase
- Development stage
- Unknown
- Lead developer
- Allendale Biosciences
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral
01
Overview
Diclofenac + paracetamol + serratiopeptidase is a fixed-dose combination oral tablet developed for the management of pain, inflammation, and edema associated with various musculoskeletal and post-operative conditions. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of pro-inflammatory prostaglandins. Paracetamol (acetaminophen) acts as an analgesic and antipyretic, primarily modulating pain and temperature-regulating centers in the central nervous system. Serratiopeptidase is a proteolytic enzyme that aids in the resolution of inflammation by breaking down abnormal proteins and inflammatory exudates, such as fibrin and bradykinin, at the site of injury. This triple combination is used to treat joint pain, muscle pain, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, dental pain, and post-operative inflammation.
- Brand names
- DICLODALE-SP
- Other names
- diclofenac potassium + paracetamol + serratiopeptidase
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)Fibrin (Factor Ia)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on diclofenac + paracetamol + serratiopeptidase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diclofenac + paracetamol + serratiopeptidase.